GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Deltex Medical Group PLC (OTCPK:DTXMF) » Definitions » ROE %

Deltex Medical Group (Deltex Medical Group) ROE % : -56.82% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Deltex Medical Group ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Deltex Medical Group's annualized net income for the quarter that ended in Dec. 2023 was $-1.89 Mil. Deltex Medical Group's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $3.32 Mil. Therefore, Deltex Medical Group's annualized ROE % for the quarter that ended in Dec. 2023 was -56.82%.

The historical rank and industry rank for Deltex Medical Group's ROE % or its related term are showing as below:

DTXMF' s ROE % Range Over the Past 10 Years
Min: -101.71   Med: -58.02   Max: -5.98
Current: -50.62

During the past 13 years, Deltex Medical Group's highest ROE % was -5.98%. The lowest was -101.71%. And the median was -58.02%.

DTXMF's ROE % is ranked worse than
77.71% of 803 companies
in the Medical Devices & Instruments industry
Industry Median: -0.45 vs DTXMF: -50.62

Deltex Medical Group ROE % Historical Data

The historical data trend for Deltex Medical Group's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deltex Medical Group ROE % Chart

Deltex Medical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.07 -28.59 -40.07 -50.25 -46.21

Deltex Medical Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.96 -53.64 -37.80 -50.82 -56.82

Competitive Comparison of Deltex Medical Group's ROE %

For the Medical Devices subindustry, Deltex Medical Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deltex Medical Group's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Deltex Medical Group's ROE % distribution charts can be found below:

* The bar in red indicates where Deltex Medical Group's ROE % falls into.



Deltex Medical Group ROE % Calculation

Deltex Medical Group's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-1.623/( (2.861+4.163)/ 2 )
=-1.623/3.512
=-46.21 %

Deltex Medical Group's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-1.886/( (2.475+4.163)/ 2 )
=-1.886/3.319
=-56.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Deltex Medical Group  (OTCPK:DTXMF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1.886/3.319
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.886 / 1.816)*(1.816 / 7.507)*(7.507 / 3.319)
=Net Margin %*Asset Turnover*Equity Multiplier
=-103.85 %*0.2419*2.2618
=ROA %*Equity Multiplier
=-25.12 %*2.2618
=-56.82 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1.886/3.319
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-1.886 / -1.888) * (-1.888 / -1.116) * (-1.116 / 1.816) * (1.816 / 7.507) * (7.507 / 3.319)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9989 * 1.6918 * -61.45 % * 0.2419 * 2.2618
=-56.82 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Deltex Medical Group ROE % Related Terms

Thank you for viewing the detailed overview of Deltex Medical Group's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Deltex Medical Group (Deltex Medical Group) Business Description

Traded in Other Exchanges
Address
Terminus Road, Chichester, W Sussex, GBR, PO19 8TX
Deltex Medical Group PLC is a British manufacturer of Fluid Management devices, which include the ODM and now ODM+ haemodynamic monitoring systems. It has developed the gold standard for haemodynamic monitoring with its oesophageal Doppler technology, which is marketed as TrueVue Doppler and often generically referred to by clinicians as ODM. The company's initial and principal technology is Doppler-based ultrasound oesophageal haemodynamic monitoring. This technology generates accurate, real-time data on descending aortic blood flow velocity in anesthetised or sedated patients.

Deltex Medical Group (Deltex Medical Group) Headlines

No Headlines